Introduction
============

In recent years, with the gradual ageing of the population and the change of dietary habits in China, the incidence of cardiovascular disease has increased gradually. Coronary heart disease has received most attention from medical workers because of its high fatality rate, especially the acute onset of coronary heart disease ([@b1-etm-0-0-6137],[@b2-etm-0-0-6137]). Acute coronary syndromes mainly include ST-segment elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UAP).

At present, coronary angiography is regarded as the gold standard in the diagnosis of coronary heart disease, which has the disadvantages of high cost and inconvenience. Thus, it is crucial to conduct the early diagnosis and effective treatment by combining with enquiry about patients medical history, as well as physical and laboratory examination ([@b3-etm-0-0-6137]--[@b5-etm-0-0-6137]). STLT-1 has a common genetic origin with the triggering receptor expressed on myeloid cells (TREM), which is a natural immune receptor activated by associated receptor proteins. Bilirubin is a bile pigment, which is the main metabolite of iron porphyrin compounds *in vivo*. It has antioxidant function and can inhibit the oxidation of linoleic acid and phospholipids.

In this study, the serum soluble TREM-like transcript-1 (STLT-1) and bilirubin levels in each group of patients were determined, so as to estimate the early diagnosis and prognosis.

Patients and methods
====================

### General data

A total of 125 patients of acute coronary syndrome and 48 cases with normal coronary angiography admitted to People\'s Hospital of Rizhao (Rizhao, China) from January 2015 to September 2016 were selected, and all of them met the standards in the guidelines of the American College of Cardiology and the American Heart Association for coronary syndromes in 2012 ([@b6-etm-0-0-6137]). There were 45 cases with STEMI, 36 cases with NSTEMI and 44 cases with UAP. The selected patients had no severe acute or chronic infection, organ dysfunction or malignancy. The statistical analysis revealed that there were no significant differences in age, sex, dietary habit and blood lipid among the patients admitted to the hospital ([Table I](#tI-etm-0-0-6137){ref-type="table"}), indicating that the data were comparable. The study was approved by the medical Ethics Committee of People\'s Hospital of Rizhao, and the patients or their families signed informed consent.

### Methods

Venous blood (3 ml) was collected using vacuum anticoagulation blood collection tube from the patients on admission. Patients in STEMI, NSTEMI and UAP groups were treated with aspirin (Bayer AG, Leverkusen, Germany) at a dose of 100 mg Qd and clopidogrel (Sanofi S.A., Paris, France) at a dose of 75 mg Qd. Fasting blood was extracted from each patient on the 3rd, 7th and 10th day after treatment. Serum levels of STLT-1 were determined using ELISA kit (Oumeng, Biotechnology Co. Ltd., Beijing, China). An ADVIA1800 automatic biochemical analyzer was used to determine serum bilirubin levels (Siemens, Berlin, Germany). The patients were followed up by telephone for a year at regular intervals after discharge. The prognosis of the patients was analyzed.

### Statistical analysis

Statistical Product and Service Solutions (SPSS) 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Measurement data are expressed as mean ± standard deviation. The analysis of variance was adopted for comparison among the groups and the post hoc test used was Dunnett test, and t-test was utilized for comparison between the groups. The Chi-square test was used for enumeration data. P\<0.05 was set as the test level.

Results
=======

### Comparison of serum levels of STLT-1 before and after treatment in each group of patients

At admission, there were no statistically significant differences in serum STLT-1 among the groups (P\>0.05). Compared with the normal control group, the serum levels of serum STLT-1 in groups STEMI, NSTEMI and UAP were higher, and the differences were statistically significant (P\<0.05). Moreover, the serum STLT levels in groups STEMI and NSTEMI were higher than those in group UAP, and the differences were statistically significant (P\<0.05). There was no statistically significant difference in comparison with serum STLT-1 level between groups STEMI and NSTEMI (P\>0.05). With the prolongation of treatment time, STLT-1 level in groups STEMI, NSTEMI and UAP was decreased (P\<0.05), and the value at each time point was different from that at the previous point, which was statistically significant ([Table II](#tII-etm-0-0-6137){ref-type="table"}).

### Comparison of serum levels of bilirubin before and after treatment in each group of patients

At admission, there were no statistically significant differences in serum bilirubin among the groups (P\>0.05). Compared with the normal control group, the serum levels of serum bilirubin in groups STEMI, NSTEMI and UAP were lower, and the differences were statistically significant (P\<0.05). Moreover, the serum bilirubin levels in groups STEMI and NSTEMI were lower than those in group UAP, and the differences were statistically significant (P\<0.05). There was no statistically significant difference in comparison with serum bilirubin level between groups STEMI and NSTEMI (P\>0.05). With the prolongation of treatment time, bilirubin level in groups STEMI, NSTEMI and UAP was increased (P\<0.05), and the value at each time point was different from that at the previous point, which was statistically significant ([Table III](#tIII-etm-0-0-6137){ref-type="table"}).

### Complications in the three groups of patients with acute coronary syndrome

The comparison in prognosis of the patients in the later stage revealed that the proportions in the occurrence of myocardial infarction, intractable angina pectoris and deep vein thrombosis (DVT) were significantly increased in groups STEMI and NSTEMI compared with those in group UAP, and the differences were statistically significant ([Table IV](#tIV-etm-0-0-6137){ref-type="table"}).

Discussion
==========

Coronary heart disease derives from coronary atherosclerosis caused by various risk factors, thus, leading to stenosis or obstruction of the blood vessels, further inducing myocardial hypoxia, or even infarction ([@b7-etm-0-0-6137]). In recent years, with the process of aging and dietary changes, the incidence of coronary heart disease in China is on the rise. If acute coronary syndrome fails to be diagnosed in time and treated effectively, it will bring great burden to the family and society due to its extremely high mortality rate ([@b8-etm-0-0-6137]). Therefore, the early diagnosis and treatment of coronary syndrome and the reduction of certain risk indicators are of great importance to rescue the endangered myocardium and ameliorate the prognosis of patients with acute coronary syndrome.

STLT-1 is a protein produced by the cleavage of TLT-1 on the surface of platelets. When the body has an inflammatory response due to various reasons, the level of STLT-1 in the serum may increase significantly ([@b9-etm-0-0-6137],[@b10-etm-0-0-6137]). Related studies indicate that STLT-1 has a promoting role in coronary heart disease. It plays a regulatory role in platelets, leukocytes and endothelial cells, which mainly adhere to vascular endothelial cells by promoting actin polymerization, thus inducing the occurrence of atherosclerosis and promoting the development of coronary heart disease ([@b11-etm-0-0-6137],[@b12-etm-0-0-6137]). The study by Esponda *et al* ([@b13-etm-0-0-6137]) indicates that STLT-1 is remarkably elevated in the serum of patients with acute coronary syndromes. The present study also confirmed that serum level of STLT-1 in patients with acute coronary syndromes was higher than that in controls, which was consistent with the above findings. The present study demonstrated that the serum levels of STLT-1 in groups STEMI and NSTEMI were higher than those in group UAP, and the proportions of complications in groups STEMI and NSTEMI were significantly higher than those in group UAP. In recent years, the study of bilirubin has indicated that it plays an important role in cardiovascular and cerebrovascular diseases. Bilirubin is a powerful antioxidant in the body, and different types of bilirubin are effective antioxidants that can scavenge oxygen free radicals from the body and protect low-density lipoproteins in the body, in order to resist the damage to the blood vessel and reduce the possibility of atherosclerosis ([@b14-etm-0-0-6137],[@b15-etm-0-0-6137]). Studies worldwide have shown that the level of bilirubin in serum is negatively-related to the incidence of coronary heart disease ([@b16-etm-0-0-6137],[@b17-etm-0-0-6137]). This study revealed that the serum bilirubin levels in groups STEMI, NSTEMI and UAP were lower than those in the normal control group, and the serum bilirubin levels in groups STEMI and NSTEMI were lower than those in group UAP.

The present study indicated that the serum level of STLT-1 was elevated with the increase of severity of acute coronary syndrome, which could gradually decrease through the effective treatment, and patients with lower STLT-1 level in the group UAP had a relatively low proportion of severe complications. The bilirubin level was lower in group STEMI than that in the normal control and UAP groups, which could be gradually enhanced after treatment, and patients with higher bilirubin level in the group UAP had a relatively low proportion of severe complications. In terms of prognosis, patients with STEMI and NSTEMI were more severe than patients with UAP. Myocardial cell damage was observed in STEMI and NSTEMI groups. It is speculated that the prognosis of STEMI and NSTEMI is worse than that of UAP. Levels of STLT-1 and bilirubin in STEMI and NSTEMI groups were also higher than those in UAP. However, further studies are needed to investigate the mechanism.

Therefore, we believe that the timely and effective treatment administered to patients with acute coronary syndrome during the initial stage to reduce the level of STLT-1 in serum and enhance bilirubin to a relatively high level is conducive in ameliorating the prognosis of patients, which has an important clinical significance.
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###### 

Comparison of general data among the four groups.

  General data           Group STEMI   Group NSTEMI   Group UAP   Group normal control   χ^2^/t   P-value
  ---------------------- ------------- -------------- ----------- ---------------------- -------- ---------
  Total                  45            36             44          48                              
  Sex (%)                                                                                         
    Male                 25            19             21          24                     3.06     0.36
    Female               20            17             23          24                     3.06     0.36
  Age (years)            57±3.24       54±3.09        52±3.11     52±3.09                1.23     0.29
                                                                                                  0.38
  Cholesterol (mmol/l)   6.12±1.2      6.02±1.1       5.89±1.2    5.99±1.2               1.11     0.59

STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UAP, unstable angina pectoris.

###### 

Comparison of serum levels of STLT-1 between and after treatment in each group of patients (pg/ml).

                        STLT-1                                                                                                                                                                                                                                                                                                                                                                                                                               
  ---------------- ---- ------------- --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------ --------
  STEMI            45   541.2±132.7   503.7±122.5^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"}--[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                             361.2±103.1^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"}--[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                            225.9±73.2^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"}--[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^   8.05   \<0.05
  NSTEMI           36   527.6±140.1   505.1±117.7^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"}[b](#tfn3-etm-0-0-6137){ref-type="table-fn"}[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^   322.5±98.2^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"}[b](#tfn3-etm-0-0-6137){ref-type="table-fn"}[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^   213.1±76.1^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"},[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^    8.16   \<0.05
  UAP              44   518.7±126.2   469.2±132.7^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"},[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                              276.3±85.1^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"},[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                              156.2±55.4^[a](#tfn2-etm-0-0-6137){ref-type="table-fn"},[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^    8.22   \<0.05
  Normal control   48   498.3±119.4   254.2±85.3^[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                                                                            112.4±41.5^[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                                                                           85.1±33.8^[c](#tfn4-etm-0-0-6137){ref-type="table-fn"}^                                                  8.21   \<0.05
  F                     1.23          8.46                                                                                                                                                8.25                                                                                                                                               8.66                                                                                                            
  P-value               \>0.05        \<0.05                                                                                                                                              \<0.05                                                                                                                                             \<0.05                                                                                                          

Compared with the normal control group, a statistically significant difference, P\<0.05

Compared with the group UAP, a statistically significant difference, P\<0.05.

The value at each time point is different from that at the previous point, and statistically significant, P\<0.05. STLT-1, soluble TREM-like transcript-1; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UAP, unstable angina pectoris.

###### 

Comparison of serum levels of bilirubin between and after treatment in each group of patients.

                        Bilirubin                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ---------------- ---- ------------ -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------ --------
  STEMI            45   10.21±3.16   12.45±3.21^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"}[b](#tfn6-etm-0-0-6137){ref-type="table-fn"}[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^   13.68±2.84^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"}[b](#tfn6-etm-0-0-6137){ref-type="table-fn"}[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^   15.42±2.54^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"}[b](#tfn6-etm-0-0-6137){ref-type="table-fn"}[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^   8.78   \<0.05
  NSTEMI           36   10.95±2.69   12.89±2.58^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"}[b](#tfn6-etm-0-0-6137){ref-type="table-fn"}[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^   14.31±2.73^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"}[b](#tfn6-etm-0-0-6137){ref-type="table-fn"}[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^   15.67±2.21^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"}[b](#tfn6-etm-0-0-6137){ref-type="table-fn"}[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^   8.84   \<0.05
  UAP              44   13.48±3.09   14.53±2.42^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"},[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^                                              15.24±2.42^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"},[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^                                              15.89±2.16^[a](#tfn5-etm-0-0-6137){ref-type="table-fn"},[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^                                              9.02   \<0.05
  Normal control   48   16.57±1.96   16.79±1.89^[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^                                                                                           16.63±1.92^[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^                                                                                           16.72±1.95^[c](#tfn7-etm-0-0-6137){ref-type="table-fn"}^                                                                                           9.21   \<0.05
  F                     1.23         8.46                                                                                                                                               8.25                                                                                                                                               8.66                                                                                                                                                      
  P-value               \>0.05       \<0.05                                                                                                                                             \<0.05                                                                                                                                             \<0.05                                                                                                                                                    

Compared with the normal control group, a statistically significant difference, P\<0.05

Compared with the group UAP, a statistically significant difference, P\<0.05.

The value at each time point is different from that at the previous point, which is statistically significant, P\<0.05. STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UAP, unstable angina pectoris.

###### 

Comparison of complications in the three groups of patients with acute coronary syndrome \[n (%)\].

  Groups    Cases (no.)   Myocardial infarction                                     Intractable angina pectoris                               Deep vein thrombosis                                      Cardiac death
  --------- ------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ---------------
  STEMI     45            6 (13.3%)^[a](#tfn8-etm-0-0-6137){ref-type="table-fn"}^   9 (20%)^[a](#tfn8-etm-0-0-6137){ref-type="table-fn"}^     4 (8.9%)^[a](#tfn8-etm-0-0-6137){ref-type="table-fn"}^    2 (4.4%)
  NSTEMI    36            5 (13.8%)^[a](#tfn8-etm-0-0-6137){ref-type="table-fn"}^   8 (22.2%)^[a](#tfn8-etm-0-0-6137){ref-type="table-fn"}^   4 (11.1%)^[a](#tfn8-etm-0-0-6137){ref-type="table-fn"}^   2 (5.6%)
  UAP       44            3 (6.8%)                                                  13 (29.5%)                                                2 (4.5%)                                                  1 (2.3%)
  χ^2^                      3.23                                                      2.39                                                      2.67                                                      2.45
  P-value                 \<0.05                                                    \<0.05                                                    \<0.05                                                    \<0.05

Compared with the group UAP, a statistically significant difference, P\<0.05. STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UAP, unstable angina pectoris; DVT, deep vein thrombosis.
